Randomized dose-controlled study of topiramate as first-line therapy in epilepsy

Area of Science:

• Neurology
• Pharmacology

Background:

• Epilepsy affects millions globally, necessitating effective monotherapy options.
• Topiramate is an established antiepileptic drug, but its optimal monotherapy dosage requires further elucidation.

Purpose of the Study:

• To assess the efficacy and tolerability of topiramate as monotherapy in a dose-controlled trial.
• To compare the effectiveness of 400 mg/day versus 50 mg/day topiramate maintenance dosages.

Main Methods:

• A multinational, randomized, double-blind trial involving adults and children (≥6 years) with epilepsy.
• Patients received either 400 mg/day or 50 mg/day topiramate as target maintenance dosages.
• Primary endpoint was time to first seizure; secondary endpoints included seizure-free rates at 6 and 12 months.

Main Results:

• The 400 mg/day dosage significantly reduced seizure frequency compared to 50 mg/day (P = 0.0002).
• Seizure-free rates at 6 months were 83% (400 mg/day) vs. 71% (50 mg/day), and at 12 months were 76% vs. 59% respectively.
• Dose-related adverse events included paresthesia and decreased appetite; cognitive adverse events led to discontinuation in 7% of the 400 mg/day group.

Conclusions:

• Topiramate is an effective monotherapy for epilepsy in both adults and children.
• Therapeutic effects emerge during dose titration, suggesting a step-wise approach to finding optimal maintenance dosages.